Banxico Survey: Private economists expect lower inflation in Mexico
On Wednesday, the Bank of Mexico (Banxico) reported that private analysts reduced their inflation expectations for the end of 2026 and updated estimates for economic growth, the exchange rate and the interbank lending rate.
Headline inflation is expected at 4.20%, down from 4.35% in the previous poll, while core figures are expected to dip from 4.22% to 4.18%.
Regarding economic growth, the Gross Domestic Product (GDP) is forecast at 1.10%, unchanged from the previous poll. For 2027, the projections remained unchanged at 1.80%.
The USD/MXN pair exchange rate is expected to end at 17.95 this year, up from 17.85, and for 2027 is projected to remain steady at 18.50.
For the interbank lending rate, the rate is expected to remain unchanged at 6.50% for the rest of the year and in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
Crypto prices
More
